KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Notes Payables: 2020-2023

Historic Notes Payables for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Dec 2023 value amounting to $41,000.

  • Recursion Pharmaceuticals' Notes Payables fell 91.68% to $55,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $55,000, marking a year-over-year decrease of 91.68%. This contributed to the annual value of $41,000 for FY2023, which is 57.73% down from last year.
  • As of FY2023, Recursion Pharmaceuticals' Notes Payables stood at $41,000, which was down 57.73% from $97,000 recorded in FY2022.
  • In the past 5 years, Recursion Pharmaceuticals' Notes Payables ranged from a high of $1.1 million in FY2020 and a low of $41,000 during FY2023.
  • Its 3-year average for Notes Payables is $76,000, with a median of $90,000 in 2021.
  • In the last 5 years, Recursion Pharmaceuticals' Notes Payables plummeted by 91.61% in 2021 and then climbed by 7.78% in 2022.
  • Yearly analysis of 4 years shows Recursion Pharmaceuticals' Notes Payables stood at $1.1 million in 2020, then tumbled by 91.61% to $90,000 in 2021, then rose by 7.78% to $97,000 in 2022, then slumped by 57.73% to $41,000 in 2023.